Global Peripheral T-Cell Lymphoma (PTCL) Market Insights, Epidemiology and Market Forecast 2016-2027 - ResearchAndMarkets.com

January 2, 2019

DUBLIN--(BUSINESS WIRE)--Jan 2, 2019--The “Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast-2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Peripheral T-Cell Lymphoma (PTCL) in the United States, the EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Peripheral T-Cell Lymphoma (PTCL) from 2016 to 2027; segmented by the seven major markets. The Report also covers the current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Key Topics Covered:

1. Report Introduction

2. Peripheral T-Cell Lymphoma (PTCL) Market Overview at a Glance

3. Disease Background and Overview: Peripheral T-Cell Lymphoma (PTCL)

4. Epidemiology and Patient Population

6. Peripheral T-Cell Lymphoma (PTCL): Country- Wise Epidemiology

7. Current Treatment & Medical Practices

8. Unmet Needs

9. Marketed Drugs

10. Emerging Therapies

11. Peripheral T-Cell Lymphoma (PTCL): Market Size

12. 7MM Peripheral T-Cell Lymphoma (PTCL): Country-Wise Market Analysis

Companies Mentioned

AB Science Celgene Corporation CerRx Onxeo S.A.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4g27r2/global_peripheral?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005346/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Lymphoma Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/02/2019 09:36 AM/DISC: 01/02/2019 09:36 AM


Update hourly